Category Archives: Tekturna

Featured Stories

Johnson & Johnson Marketing of Gynecare Prolift Transvaginal Mesh Raises More Questions

Johnson & Johnson and its Ethicon unit are again coming under scrutiny for the way it marketed its Gynecare ProLift transvaginal mesh product. According to a new report from Bloomberg News, Johnson & Johnson continued marketing the Gynecare ProLift device for months after it received a warning from the ...

Read More

Parker Waichman Representing Another Louisiana Plaintiff in Actos Bladder Cancer Lawsuit

A Louisiana man has become the latest to claim that his taking the type 2 diabetes drug Actos resulted in developing bladder cancer. He has filed a lawsuit against the Japanese manufacturer of the drug and the marketer of it in the U.S., claiming they failed to warn about this ...

Read More

FDA Warning for Bone Graft Products in Patients Under 18

FDA Safety Warning for Bone Graft Products in Patients Under 18

FDA issued safety alerts to patients, parents & guardians, bone graft devices w/recombinant proteins or synthetic peptides not to be the first treatment for 18 & under.

Read More

Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee Resident

Actos bladder cancer lawsuits continue, with a new complaint filed by a resident of Tennessee. The national law firm, Parker Waichman LLP, represents the Tennessee man who alleges that Actos caused his bladder cancer.

Read More

Cancer Groups Call for E-cigarettes Regulation/Research

Two Leading Cancer Groups Issue Call for Regulation of E-cigarettes and Research on Health Risks

In a joint statement, the American Society of Clinical Oncology and the American Association for Cancer Research have called on the federal government to move quickly to regulate e-cigarettes and increase research on their health effects. These leading research and treatment organizations asked the Food and Drug Administration (FDA) to make ...

Read More

Federal Judge Certifies Medtronic Infuse Shareholder Class Action Lawsuit

A shareholder lawsuit alleging Medtronic Inc. illegally promoted the off-label use of its Infuse bone growth product has been granted class action status by U.S. District Judge Paul Magnuson of Minnesota. According to a report from Law360.com, the Medtronic Infuse off-label promotion lawsuit was filed by several institutional investors on ...

Read More

System for Tracking Prescription Drug Side Effects Flawed

Study Finds System for Tracking Prescription Drug Side Effects Flawed

System for keeping track of dangerous side effects of prescription drugs is flawed because drug makers are submitting incomplete information about problems to the FDA.

Read More

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

Crash on N.State Pkwy Kills Port Jefferson Station Man

Single-Car Crash on Northern State Parkway Kills Port Jefferson Station Man

81-year-old Port Jefferson Station man was killed in a crash at 4:57 a.m.. He lost control of the vehicle traveling west on Northern State Pkwy, on exit 42, Dix Hills.

Read More

Drug Maker, Novartis, Accused Again of Kickback Schemes

We have long noted that the financial relationships between the drug and the health care industries have led to enormous controversy. Critics maintain that such relationships create conflicts of interest and could unduly influence everything from research findings to prescribing … Continue reading

Posted in Consumer Fraud, Legal News, Pharmaceuticals, Tekturna |

U.S. Prosecutors Investigating Novartis Marketing of Blood Pressure Drug Tekturna

U.S. prosecutors are investigating European drug manufacturer Novartis for its marketing of products including hypertension drug Tekturna. In a recent regulatory filing, Swiss-based Novartis revealed that, last year, a U.S. unit of the company received a subpoena from federal prosecutors … Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals, Tekturna |

Analysis of adverse event reports questions benefit of blood pressure drug Tekturna

A recent analysis of adverse health events linked to certain prescription drugs identified 100 incidents linked to the blood pressure medication Tekturna in just the first part of this year. The Institute for Safe Medication Practices (ISMP) combed a database … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna Linked to Significant Number of Adverse Events

Independent watchdog group, the Institute for Safe Medical Practices (ISMP) reports a 90 percent increase in significant adverse drug event reports received by the U.S. Food & Drug Administration (FDA) over the past four years. Among these, are events associated … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna Label Changes, Valturna Market Withdrawal Announced by Novartis

Novartis announced yesterday that the label for the blood pressure drug Tekturna (aliskiren) will be updated with new warnings regarding its use in people with diabetes and kidney problems. Novartis also announced it will no longer market Valturna, a single-pill … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna (Aliskiren) Associated with Serious Side Effects, Including Stroke, Severe Kidney Damage

Tekturna (aliskiren) and other medications containing aliskiren have been associated with serious side effects, including non-fatal stroke and severe kidney damage, in some patients. Tekturna and other aliskiren products were recently the subject of safety warnings in Europe (where it … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

MHRA Issues New Contraindications, Recommendations for Rasilez (Aliskiren) with ACE Inhibitors, ARBs

Health regulators in the U.K. have announced new contraindications and warnings regarding Rasilez (aliskiren), a blood pressure drug which is sold as Tekturna in the U.S. According a Drug Safety Update issued by the Medicine and Healthcare Products Regulatory Agency, … Continue reading

Posted in Pharmaceuticals, Tekturna |

Novartis Updates Rasilez Label in Europe with New Warnings for Diabetes, Kidney Patients

The blood pressure drug Rasilez – sold in the U.S. under the brand name Tekturna – will soon bear new safety warnings on its European label, after a clinical trial was halted because subject patients experienced a high rate of … Continue reading

Posted in Pharmaceuticals, Tekturna |

Canada Issues Warning, Updates Labeling For Rasilez

Canada just issued a warning for Rasilez, a high blood pressure drug known as Tekturna in the United States. Novartis Pharmaceuticals, Canada Inc makes Rasilez. Health Canada and Novartis issued the warning for aliskiren-containing products, Rasilez and Rasilez HCT, after … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna To Undergo Canadian Safety Review

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions. “Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) … Continue reading

Posted in Tekturna |

© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.